Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 17/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939424 | 0.91 | SLC6A9 (0.56) | SLC6A9GPR55CNR1SLC6A5ALDH1A1 | |
| SCHEMBL4933835 | 0.88 | SLC6A9 (0.70) | SLC6A9GPR55CNR1SLC6A5ALDH1A1 | |
| SCHEMBL4939425 | 0.88 | SLC6A9 (0.53) | SLC6A9KCNH2GPR55CNR1SLC6A5 | |
| SCHEMBL4934646 | 0.86 | SLC6A9 (0.72) | SLC6A9GPR55CNR1SLC6A5ALDH1A1 | |
| SCHEMBL4937518 | 0.85 | SLC6A9 (0.61) | SLC6A9KCNH2GPR55CNR1SLC6A5 | |
| SCHEMBL4937072 | 0.85 | SLC6A9 (0.60) | SLC6A9KCNH2GPR55CNR1SLC6A5 | |
| SCHEMBL4930270 | 0.84 | SMN1; SMN2 (0.59) | SLC6A9GPR55ALDH1A1LMNAMAPT | |
| SCHEMBL8256322 | 0.81 | SMN1; SMN2 (0.55) | SLC6A9GPR55ALDH1A1LMNAMAPT | |
| SCHEMBL4935893 | 0.80 | SLC6A9 (0.72) | SLC6A9GPR55CNR1SLC6A5LMNA | |
| SCHEMBL4936664 | 0.80 | GPR55 (0.58) | SLC6A9GPR55CNR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | SLC6A9 22/4885KCNH2 691/4885GPR55 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.